Sarbajit Mukherjee

Medical Oncology
Buffalo Spree Top Doctor 2024

Dr. Mukherjee is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2024

Cancers Treated:

Research Interests:

Use of immune checkpoint inhibitors in solid tumors

About Sarbajit Mukherjee


I am a gastrointestinal medical oncologist with a research focus on novel clinical trials and cancer immunotherapy. I have gained experience in translational research and clinical trial design through a Master's program in clinical and translational science. My current work involves understanding the biology of gastrointestinal cancers and designing novel clinical trials to improve patient outcomes. Besides, I am interested in studying mechanisms of immune dysfunction in obese cancer patients and the use of immune checkpoint inhibitors in solid tumors. I have led over a dozen clinical trials as a Principal Investigator (PI) and received six grants as a PI or co-investigator. Many of my studies are investigator-initiated and grant-funded through national organizations like the National Cancer Institute (NCI) and the department of defense (DOD). My work has resulted in several national/international presentations and peer-reviewed publications in high-impact journals. As a physician-scientist, my goal is to conduct innovative clinical trials using novel immunotherapy agents and take discoveries from the lab to the bedside to improve life expectancy as well as the quality of life of cancer patients. As an educator, I strive to improve the quality of oncology education and mentor the next generation of clinician investigators.

I have had the opportunity to serve the American Society of Clinical Oncology (ASCO). I have been a member of the Trainee Council Working Group, Clinical Practice Guidelines Committee, and the Professional Development Committee at ASCO. I have also served on multiple guidelines panels for ASCO. Currently, I am a guidelines panel member at the National Comprehensive Cancer Network and at the International Society for Diseases of the Esophagus. 

I have been fortunate to receive many national and international awards. I have been asked to review manuscripts for reputed journals and grant applications for federal funding agencies.

For me, caring for a cancer patient is more than treating a disease; it's a healing process involving both the patient's body, mind, and caregivers. I would like to see myself as a successful clinical and translational researcher and a compassionate physician, and a thought leader in the field of gastrointestinal cancers.


Roswell Park Comprehensive Cancer
  • Associate Professor of Oncology
  • Department of Medicine
  • Department of Immunology
  • Co-Leader, GI Translational Research Group

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • Assistant Professor


Education and Training:

  • 2010 - MD - Nilratan Sircar Medical College, West Bengal University of Health Sciences, India
  • 2018 - MS - Master of Science in Clinical and Translational Science, University of Oklahoma, Oklahoma City, OK


  • 2012-2015 - Saint Joseph Hospital, Chicago, IL


  • 2015-2018 - University of Oklahoma Health Sciences Center, Oklahoma City, OK

Board Certification:

  • 2018 - Medical Oncology - American Board of Internal Medicine
  • 2018 - Hematology - American Board of Internal Medicine
  • 2015 - Internal Medicine - American Board of Internal Medicine

Professional Memberships:

  • Society for Immunotherapy of Cancer
  • American Association for Cancer Research
  • American College of Gastroenterology
  • North American Neuroendocrine Tumor Society
  • European Society of Medical Oncology
  • American Society of Clinical Oncology

Professional Experience:

  • 2023-present - Co-chair, HCRN GI Clinical Trial Working Group
  • 2021-present - Quality Subcommittee, Society for Immunotherapy of Cancer (SITC)
  • 2018-present - Board of Directors, Esophageal Cancer Action Network
  • 2017-2018 - Chief fellow, Hematology-Oncology, University of Oklahoma
  • 2017-2018 - Clinical Practice Guidelines Committee, ASCO
  • 2016-2018 - Professional Development Committee, ASCO

Honors & Awards:

  • Clinical Investigator Scholarship Award, North American Neuroendocrine Tumor Society
  • ASCO/AACR Methods in Clinical Cancer Workshop, Vail, CO
  • James N. George award for the outstanding fellow in hematology-oncology, University of Oklahoma
  • Gold Humanism Honor Society
  • Conquer Cancer Foundation Merit Award, ASCO
  • Alpha Omega Alpha (AOA) Honor Medical Society
  • Early Career Reviewer, Developmental Therapeutics (DT), Center for Scientific Review, National Institutes of Health
  • Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Network (SCION) Workshop participant
  • Young Investigator Award, ESMO World Congress on Gastrointestinal Cancer

Clinical Trials

Featured on Cancer Talk


Full Publications list on PubMed

1. Rosario SR, Dong B, Zhang Y, Hsiao H-H, Isenhart E, Wang J, Siegel EM, Monjazeb AM, Owen DH, Dey P, Tabung FK, Spakowicz DJ, Murphy WJ, Edge S, Yendamuri S, Ibrahimi S, Kolesar JM, McDonald PH, Vadehra D, Churchman M, Liu S, Kalinski P, Mukherjee S. Metabolic Dysregulation Explains the Diverse Impacts of Obesity in Males and Females with Gastrointestinal Cancers. International Journal of Molecular Sciences. 2023; 24(13):10847. Published 2023 Jun 29. PMID: 37446025.

2. Parmar K, Subramanyam S, Attwood K, Appiah D, Fountzilas C, Mukherjee S. Anti PD-1/Anti PDL-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Pharmaceutics. 2022;14(9):1953. PMID: 36145703

3. Deng L, Groman A, Jiang C, Perimbeti S, Gabriel E, Kukar M, Mukherjee S. Association of Preoperative Chemosensitivity With Postoperative Survival in Patients With Resected Gastric Adenocarcinoma. JAMA Netw Open. 2021 Nov 1;4(11): e2135340. PMID: 34797369.

4. Gosain R, Ball S, Rana N, Groman A, Gage-Bouchard E, Dasari A, Mukherjee S. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study. Cancer. 2020 Feb 15;126(4):792-799. PubMed PMID: 31714595.

5. Mukherjee S, Fountzilas C, Boland PM, Gosain R, Attwood K, Tan W, Khushalani N, Iyer R. Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Target Oncol. 2019 Dec 4. PubMed PMID: 31802410.